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The number of people with type 2 diabetes mellitus (T2DM)
has been increasing worldwide due to aging, urbanization,
dietary, and lifestyle changes. It was estimated that there were
415 million people with diabetes aged 20–79 years in 2015,
and the number was predicted to rise to 642 million by
2040 [1]. With comprehensive control of risk factors of
cardiovascular disease (CVD), there has been a decline in
prevalence and mortality from diabetic macrovascular
complications over the past several decades in some
western countries including United States of America.
Macrovascular complications, mainly including cardiovas-
cular and cerebrovascular diseases, are still the most
common complications and the major cause of mortality
and morbidity in patients with T2DM.
In recent years, there are several advances in this ﬁeld.
Diabetes patients usually have hyperglycemia, hyperlipid-
emia, and insulin resistance; all of them are risk factors for
macrovascular diseases. PKCs, RAGE, and ROS may mediate
the eﬀects of hyperglycemia and hyperlipidemia on cardio-
vascular systems. Knockout of PKCβ, RAGE, and Nox1
could attenuate the development of atherosclerosis in
diabetic mice [2, 3]. To mimic endothelial or macrophage
insulin resistance, insulin receptor was specially knocked
out in endothelial cells or macrophages. The development
of atherosclerosis was accelerated in endothelial speciﬁc
insulin receptor knockout mice, and the plaque was more
unstable in macrophages-speciﬁc insulin receptor knockout
mice. Look AHEAD trial and the Italian Diabetes and Exer-
cise Study indicate that lifestyle management signiﬁcantly
improves physical ﬁtness, A1c, and coronary heart disease
(CHD) risk factors. Weight loss surgery, especially bariatric
surgery, could result in weight loss, A1c improvement [4],
and CVD outcome improvement. Furthermore, data are
available about the eﬀect of glucose-lowering therapies on
cardiovascular risk in patients with T2DM. In addition, clinic
trials have demonstrated that with comprehensive manage-
ment of CVD risk, factors such as lowering blood glucose,
smoking rate, and total cholesterol as well as blood pressure
mortality rates from macrovascular complications have been
declining steadily in some countries.
In this issue, T. Hu et al. found that decreased expression
of CSE and 3-MST and the subsequently decreased produc-
tion of hydrogen sulﬁde (H2S) contributed to high glucose-
(HG-) induced sFlt-1 production via activating ADAM17
in adipocytes. Exogenous H2S donor NaHS has a potential
therapeutic value for HG-induced sFlt-1 production. S. Ye
et al. found that the traditional Chinese medicine Didang
Decoction intervention could upregulate the expression of
cAMP-1 and PKA and downregulate the expression level of
MLCK and PKC, thus ameliorating vascular endothelium
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injury in high-fat diet followed by the small dose of STZ-
induced diabetic animal model.
T2DM is always accompanied by a cluster of risk factors
of CVD such as high blood pressure, dyslipidemia, central
obesity, and albuminuria [5]. M.-F. Yao et al. explored the
diﬀerences in the risks of CHD and stroke between Chi-
nese women and men with T2DM and their association
with metabolic syndrome in Hangzhou, China. They
found that women had lower CHD risk, fatal CHD risk,
stroke risk, and fatal stroke risk compared with men with
T2DM. The CHD risk was signiﬁcantly higher in men
with MS than in those without MS; and the CHD and
stroke risks were higher in women with MS than in those
without MS. In a total of 9473 subjects aged over 45 years,
including 1648 patients with T2DM, X. Ding et al. found
that the patients with prediabetes or T2DM were with
higher risks to have hypertension. T2DM with nonalco-
holic fatty liver disease (NAFLD) had signiﬁcantly higher
levels of blood pressure, triglyceride, uric acid, and
HOMA-IR than those without NAFLD. Hypertriglyc-
eridemia, NAFLD, hyperuricemia, and insulin resistance
were associated with a higher prevalence of hypertension
independent of other metabolic risk factors in type 2 dia-
betes. B. Stratmann et al. found that serum phospholipid
and serine levels independently discriminated T2D patients
with and without CAD. Oxidative stress, which is increased
in T2D, leads to profound changes in the content and com-
position of biological membranes and accelerated phospho-
lipid degradation, resulting in lower metabolite levels of
PCs and serine.
Lower extremity peripheral arterial disease (PAD) is a
common type of PAD in patients with T2DM, which can
be noninvasively and objectively diagnosed by using the
ankle-brachial index (ABI), and is also a marker of arterial
atherosclerosis at other sites [6]. J. Ma et al. evaluated the con-
cordance between oscillometric ABI and standard Doppler
ABI in diabetic patients with or without diabetic foot. They
found that the oscillometric measurement was proven to be
a reliable, convenient, and less time-consuming alternative
to standard Doppler ABI in patients. X.-H. Pang et al. deter-
mined the relationship between lower extremity peripheral
arterial disease (PAD), 10-year CHD, and stroke risks in
patients with type 2 diabetes. They found that 88 (7.5%)
patients were detected with PAD in 1178 T2DM patients.
ABI was an independent predictor of 10-year CHD and
stroke risks in T2DM patients. Compared with those in the
T2DM non-PAD group, the odds ratios (ORs) for CHD
and stroke risk were 3.6 (95% conﬁdence interval (CI),
2.2–6.0; P< 0 001) and 6.9 (95% CI, 4.0–11.8; P< 0 001) in
those with lower extremity PAD, respectively.
Coronary revascularization is a safe and eﬀective therapy
for patients with single and multivessel coronary artery dis-
ease. Patients with diabetes mellitus contribute to about 25%
of patients undergoing coronary revascularization [7]. Coro-
nary artery bypass grafting (CABG) surgery is considered a
standard of care for patients with advanced coronary artery
disease. The optimal glycosylated hemoglobin (HbA1C)
target may be especially pertinent in diabetic patients with
coronary artery diseases. J. Zheng et al. made a meta-
analysis and systemic review including 7895 diabetic
patients undergoing coronary artery bypass grafting surgery
from eight published studies. Combined analyses revealed
that higher HbA1c level was signiﬁcantly associated with
increased risks of all-cause mortality, myocardial infarction,
and stroke in diabetic subjects undergoing CABG surgery.
In conclusion, there is ongoing progress in the patho-
physiology, glycemia control, and risk factors of diabetic
macrovascular complications shown in this special issue.
Several other ﬁelds are also showing progress, such as weight
loss surgery, but these are not discussed in the present issue.
We believe that the present issue could bring some latest
progress in this ﬁeld and will be of interest to the readers.
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